Literature DB >> 29305136

Low-level dystrophin expression attenuating the dystrophinopathy phenotype.

Megan A Waldrop1, Felecia Gumienny2, Saleh El Husayni3, Diane E Frank3, Robert B Weiss4, Kevin M Flanigan5.   

Abstract

The reading frame rule suggests that Duchenne muscular dystrophy (DMD) results from DMD mutations causing an out-of-frame transcript, whereas the milder Becker muscular dystrophy results from mutations causing an in-frame transcript. However, predicted nonsense mutations may instead result in altered splicing and an in-frame transcript. Here we report a 10-year-old boy with a predicted nonsense mutation in exon 42 who had a 6-minute walk time of 157% of that of age matched DMD controls, characterized as intermediate muscular dystrophy. RNA sequencing analysis from a muscle biopsy revealed only 6.0-9.8% of DMD transcripts were in-frame, excluding exon 42, and immunoblot demonstrated only 3.2% dystrophin protein expression. Another potential genetic modifier noted was homozygosity for the protective IAAM LTBP4 haplotype. This case suggests that very low levels of DMD exon skipping and dystrophin protein expression may result in amelioration of skeletal muscle weakness, a finding relevant to current dystrophin-restoring therapies.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dystrophin; Intermediate muscular dystrophy; Nonsense mutation; RNA sequencing

Mesh:

Substances:

Year:  2017        PMID: 29305136      PMCID: PMC9460236          DOI: 10.1016/j.nmd.2017.11.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   3.538


  28 in total

1.  Becker muscular dystrophy due to an inversion of exons 23 and 24 of the DMD gene.

Authors:  Kevin M Flanigan; Diane Dunn; C Aaron Larsen; Livija Medne; Carsten B Bönnemann; Robert B Weiss
Journal:  Muscle Nerve       Date:  2011-11       Impact factor: 3.217

2.  Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene.

Authors:  Nathalie Deburgrave; Fatma Daoud; Stéphane Llense; Jean Claude Barbot; Dominique Récan; Cécile Peccate; Arthur H M Burghes; Christophe Béroud; Luis Garcia; Jean-Claude Kaplan; Jamel Chelly; France Leturcq
Journal:  Hum Mutat       Date:  2007-02       Impact factor: 4.878

Review 3.  Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule.

Authors:  Annemieke Aartsma-Rus; Judith C T Van Deutekom; Ivo F Fokkema; Gert-Jan B Van Ommen; Johan T Den Dunnen
Journal:  Muscle Nerve       Date:  2006-08       Impact factor: 3.217

4.  Eteplirsen for the treatment of Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Louise R Rodino-Klapac; Zarife Sahenk; Kandice Roush; Loren Bird; Linda P Lowes; Lindsay Alfano; Ann Maria Gomez; Sarah Lewis; Janaiah Kota; Vinod Malik; Kim Shontz; Christopher M Walker; Kevin M Flanigan; Marco Corridore; John R Kean; Hugh D Allen; Chris Shilling; Kathleen R Melia; Peter Sazani; Jay B Saoud; Edward M Kaye
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

5.  Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.

Authors:  N Shiga; Y Takeshima; H Sakamoto; K Inoue; Y Yokota; M Yokoyama; M Matsuo
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.

Authors:  Kevin M Flanigan; Diane M Dunn; Andrew von Niederhausern; Payam Soltanzadeh; Michael T Howard; Jacinda B Sampson; Kathryn J Swoboda; Mark B Bromberg; Jerry R Mendell; Laura E Taylor; Christine B Anderson; Alan Pestronk; Julaine M Florence; Anne M Connolly; Katherine D Mathews; Brenda Wong; Richard S Finkel; Carsten G Bonnemann; John W Day; Craig McDonald; Robert B Weiss
Journal:  Hum Mutat       Date:  2011-03       Impact factor: 4.878

7.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

8.  Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years.

Authors:  Nathalie Goemans; Katrijn Klingels; Marleen van den Hauwe; Stefanie Boons; Liese Verstraete; Charlotte Peeters; Hilde Feys; Gunnar Buyse
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes.

Authors:  Jonàs Juan-Mateu; Lidia González-Quereda; Maria José Rodríguez; Edgard Verdura; Kira Lázaro; Cristina Jou; Andrés Nascimento; Cecilia Jiménez-Mallebrera; Jaume Colomer; Soledad Monges; Fabiana Lubieniecki; Maria Eugenia Foncuberta; Samuel Ignacio Pascual-Pascual; Jesús Molano; Montserrat Baiget; Pia Gallano
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

10.  Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

Authors:  Richard S Finkel; Kevin M Flanigan; Brenda Wong; Carsten Bönnemann; Jacinda Sampson; H Lee Sweeney; Allen Reha; Valerie J Northcutt; Gary Elfring; Jay Barth; Stuart W Peltz
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

View more
  14 in total

1.  Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications.

Authors:  Alberto A Zambon; Megan A Waldrop; Roxane Alles; Robert B Weiss; Sara Conroy; Melissa Moore-Clingenpeel; Stefano Previtali; Kevin M Flanigan
Journal:  Neurology       Date:  2021-12-22       Impact factor: 9.910

2.  DOCK3 is a dosage-sensitive regulator of skeletal muscle and Duchenne muscular dystrophy-associated pathologies.

Authors:  Andrea L Reid; Yimin Wang; Adrienne Samani; Rylie M Hightower; Michael A Lopez; Shawn R Gilbert; Lara Ianov; David K Crossman; Louis J Dell'Italia; Douglas P Millay; Thomas van Groen; Ganesh V Halade; Matthew S Alexander
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

Review 3.  CRISPR for Neuromuscular Disorders: Gene Editing and Beyond.

Authors:  Courtney S Young; April D Pyle; Melissa J Spencer
Journal:  Physiology (Bethesda)       Date:  2019-09-01

Review 4.  Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies.

Authors:  Ahlke Heydemann
Journal:  Nutrients       Date:  2018-06-20       Impact factor: 5.717

5.  Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.

Authors:  Diane E Frank; Frederick J Schnell; Cody Akana; Saleh H El-Husayni; Cody A Desjardins; Jennifer Morgan; Jay S Charleston; Valentina Sardone; Joana Domingos; George Dickson; Volker Straub; Michela Guglieri; Eugenio Mercuri; Laurent Servais; Francesco Muntoni
Journal:  Neurology       Date:  2020-03-05       Impact factor: 9.910

Review 6.  Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Dongsheng Duan
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

Review 7.  Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update.

Authors:  Chengmei Sun; Luoan Shen; Zheng Zhang; Xin Xie
Journal:  Genes (Basel)       Date:  2020-07-23       Impact factor: 4.096

8.  Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.

Authors:  Eric P Hoffman
Journal:  Acta Myol       Date:  2020-12-01

9.  A Muscle Hybrid Promoter as a Novel Tool for Gene Therapy.

Authors:  Katarzyna Piekarowicz; Anne T Bertrand; Feriel Azibani; Maud Beuvin; Laura Julien; Magdalena Machowska; Gisèle Bonne; Ryszard Rzepecki
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-12       Impact factor: 6.698

10.  Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy.

Authors:  Yvan de Feraudy; Rabah Ben Yaou; Karim Wahbi; Caroline Stalens; Amalia Stantzou; Vincent Laugel; Isabelle Desguerre; Laurent Servais; France Leturcq; Helge Amthor
Journal:  Ann Neurol       Date:  2020-11-24       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.